Kintara Therapeutics Inc Aktie News

NEW YORK , June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TuHURA Biosciences, Inc. (NASDAQ: HURA)'s  merger with Kineta, Inc. If you are a TuHURA shareholder, click here to learn more about your legal right...

Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025 Resolution of partial clinical hold unlocks second tran...

Secures $12.5 million of commitments in a private offering Secures an additional $3.0 million through payment of cash exercise price of warrants Funding provides capital for: Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2-2025 year end Acquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a novel VISTA inhibiting antibody through c...

Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) ...

Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA), in Q2 2025 Initiated a Phase 1b/2a trial of IFx-Hu2.0 as adjunctive ther...

TAMPA, Fla. , May 13, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A.

Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda ®  when administered via Interventional Radiology (IR) in patients with deep- seated tumors without associated cutaneous tumors TAMPA, Fla. , May 5, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel ...

Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg dose level throughout the trial's every two weekly dosing interval (Q2W) TuHURA's Phase 3-ready IFx2.0 produced clinically meaningful anti-tumor responses and abscopal effect, after checkpoint inhibitor (CPI) therapy failure in patients with advanced melanoma when recha...